OBJECTIVES: To characterize the clinical course of mucopolysaccharidosis type IIIA (MPS IIIA), and identify potential endpoints for future treatment trials. STUDY DESIGN: Children with a confirmed diagnosis of MPS IIIA, functioning above a developmental age of 1 year, were followed for up to 2 years. Cognitive status and brain atrophy were assessed by standardized tests and volumetric magnetic resonance imaging, respectively. Liver and spleen volumes and cerebrospinal fluid and urine biomarker levels were measured. RESULTS: Twenty-five children, from 1.1 to 18.4 years old, were enrolled, and 24 followed for at least 12 months. 19 exhibited a rapidly progressing (RP) form of MPS IIIA, and 5, a more slowly progressing form. Children with RP plateaued in development by 30 months, followed by rapid regression after 40-50 months. In patients with RP, cognitive developmental quotients showed consistent steep declines associated with progressive cortical gray matter atrophy. Children with slowly progressing had a similar but more prolonged course. Liver and spleen volumes were approximately double normal size, and cerebrospinal fluid and urine heparin sulfate levels were elevated and relatively constant over time. CONCLUSION: Developmental quotient and cortical gray matter volume are sensitive markers of disease progression in MPS IIIA, and may have utility as clinical endpoints in treatment trials. For optimal outcomes, treatment may need to be instituted in children before the onset of steep cognitive decline and brain atrophy. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01047306.
OBJECTIVES: To characterize the clinical course of mucopolysaccharidosis type IIIA (MPS IIIA), and identify potential endpoints for future treatment trials. STUDY DESIGN:Children with a confirmed diagnosis of MPS IIIA, functioning above a developmental age of 1 year, were followed for up to 2 years. Cognitive status and brain atrophy were assessed by standardized tests and volumetric magnetic resonance imaging, respectively. Liver and spleen volumes and cerebrospinal fluid and urine biomarker levels were measured. RESULTS: Twenty-five children, from 1.1 to 18.4 years old, were enrolled, and 24 followed for at least 12 months. 19 exhibited a rapidly progressing (RP) form of MPS IIIA, and 5, a more slowly progressing form. Children with RP plateaued in development by 30 months, followed by rapid regression after 40-50 months. In patients with RP, cognitive developmental quotients showed consistent steep declines associated with progressive cortical gray matter atrophy. Children with slowly progressing had a similar but more prolonged course. Liver and spleen volumes were approximately double normal size, and cerebrospinal fluid and urine heparin sulfate levels were elevated and relatively constant over time. CONCLUSION: Developmental quotient and cortical gray matter volume are sensitive markers of disease progression in MPS IIIA, and may have utility as clinical endpoints in treatment trials. For optimal outcomes, treatment may need to be instituted in children before the onset of steep cognitive decline and brain atrophy. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01047306.
Authors: Ann Meyer; Kai Kossow; Andreas Gal; Cordula Steglich; Chris Mühlhausen; Kurt Ullrich; Thomas Braulke; Nicole Muschol Journal: Hum Mutat Date: 2008-05 Impact factor: 4.878
Authors: Hicham Naimy; Kendall D Powell; John R Moriarity; Jiang Wu; Thomas G McCauley; Patrick Aj Haslett; Ann J Barbier; Yongchang Qiu Journal: Bioanalysis Date: 2016-02-05 Impact factor: 2.681
Authors: Adeline A Lau; Barbara M King; Carly L Thorsen; Sofia Hassiotis; Helen Beard; Paul J Trim; Lauren S Whyte; Sarah J Tamang; Stephen K Duplock; Marten F Snel; John J Hopwood; Kim M Hemsley Journal: J Inherit Metab Dis Date: 2017-04-27 Impact factor: 4.982
Authors: Elsa Shapiro; Jessica Bernstein; Heather R Adams; Ann J Barbier; Teresa Buracchio; Peter Como; Kathleen A Delaney; Florian Eichler; Jonathan C Goldsmith; Melissa Hogan; Sarrit Kovacs; Jonathan W Mink; Joanne Odenkirchen; Melissa A Parisi; Alison Skrinar; Susan E Waisbren; Andrew E Mulberg Journal: Mol Genet Metab Date: 2016-04-14 Impact factor: 4.797
Authors: E Shapiro; K King; A Ahmed; K Rudser; R Rumsey; B Yund; K Delaney; I Nestrasil; C Whitley; M Potegal Journal: Mol Genet Metab Rep Date: 2016-03-01
Authors: Suzan J G Knottnerus; Stephanie C M Nijmeijer; Lodewijk IJlst; Heleen Te Brinke; Naomi van Vlies; Frits A Wijburg Journal: Ann Neurol Date: 2017-10-26 Impact factor: 10.422